Who are Curis, Inc.'s main suppliers?

Curis, Inc. (CRIS) key suppliers include: AURIGENE, TPC-INVESTMENTS-ROYALTY-LLC, OBERLAND, OBERLAND-CAPITAL-MANAGEMENT-LLC. View the full supplier network at chainsifter.com/chain/CRIS.

Who are Curis, Inc.'s major customers?

Curis, Inc. (CRIS) key customers include: GENENTECH, ROCHE, TPC-INVESTMENTS-ROYALTY-LLC, Bio-Path Holdings, Inc., Bio-Path Holdings, Inc. and 17 more. View the full customer network at chainsifter.com/chain/CRIS.

What sector is Curis, Inc. in?

Curis, Inc. (CRIS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Curis, Inc. Suppliers, Customers & Supply Chain (CRIS)

4Suppliers

22Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Curis, Inc. (CRIS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships

4Distinct source URLs

11High confidence

0.767Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Curis, Inc. Suppliers

Ticker	Name	Confidence	Evidence
AURIGENE	AURIGENE	85%	The Company is party to an exclusive collaboration agreement with Aurigene for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and selecte…
TPC-INVESTMENTS-ROYALTY-LLC	TPC-INVESTMENTS-ROYALTY-LLC	85%	As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited liability company managed by Oberland, its interest in Curis Royalty LLC
OBERLAND	OBERLAND	80%	As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited liability company managed by Oberland, its interest in Curis Royalty LLC
OBERLAND-CAPITAL-MANAGEMENT-LLC	OBERLAND-CAPITAL-MANAGEMENT-LLC	80%	Prior to the sale of Erivedge, a significant portion of royalty revenues received from Genentech on net sales of Erivedge was paid to Oberland pursuant to the Oberland Purchase Agreement.

Curis, Inc. Customers

Ticker	Name	Confidence	Evidence
GENENTECH	GENENTECH	92%	Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ®
ROCHE	ROCHE	90%	Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ®
TPC-INVESTMENTS-ROYALTY-LLC	TPC-INVESTMENTS-ROYALTY-LLC	90%	In November 2025, the Company sold Erivedge to TPC Investments Royalty LLC, a limited liability company managed by Oberland Capital Management, LLC, in exchange for upfront consideration of $2.5 million.
BPTH	Bio-Path Holdings, Inc.	72%	Reciprocal relationship from BPTH graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by…
BPTH	Bio-Path Holdings, Inc.	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from GILD g…
GILD	Gilead Sciences, Inc.	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from CRIS graph: to the processing of personal data th…
JNJ	Johnson & Johnson	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from LLY grap…
LLY	Eli Lilly and Company	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
NRIX	Nurix Therapeutics, Inc.	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
NRIX	Nurix Therapeutics, Inc.	72%	Reciprocal relationship from NRIX graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by…
RIGL	Rigel Pharmaceuticals, Inc.	72%	Reciprocal relationship from RIGL graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from CRIS graph: to the processing of personal data …
RIGL	Rigel Pharmaceuticals, Inc.	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
STTK	Shattuck Labs, Inc.	72%	Reciprocal relationship from STTK graph: Reciprocal relationship from CRIS graph: to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by…
STTK	Shattuck Labs, Inc.	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
VINC	Vincerx Pharma, Inc.	72%	Reciprocal relationship from VINC graph: Reciprocal relationship from CRIS graph: Reciprocal relationship from VINC graph: Reciprocal relationship from CRIS graph: to the processing of personal data …
VINC	Vincerx Pharma, Inc.	72%	to the processing of personal data that takes place in the UK and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the UK and the EU have determined, thro…
F-HOFFMANN-LA-ROCHE-LTD	F-HOFFMANN-LA-ROCHE-LTD	62%	The Company's operations are located entirely within the U.S. The Company's focus is primarily on the development of emavusertib, a small molecule IRK4/FLT3 inhibitor. The Company was party to a coll…
LA-ROCHE-LTD	LA-ROCHE-LTD	62%	La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist approved for the treatment of advanced bas…
ROCHE-GROUP	ROCHE-GROUP	62%	The Company's operations are located entirely within the U.S. The Company's focus is primarily on the development of emavusertib, a small molecule IRK4/FLT3 inhibitor. The Company was party to a coll…

Curis, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
CRIS-DEBT-60634	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2026-03-31.
CRIS-DEBT-8853	Warrants outstanding: 1373517	90%	xbrl warrant detail from xbrl 2024-12-31.
CRIS-DEBT	Debt stack $6.9M	90%	Market cache reports total debt of $6.9M.

Curis, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Curis, Inc..

Curis, Inc. Ownership

Holder	Name	Confidence	Evidence
CRIS-OWNER-BLEICHROEDER-LP	Bleichroeder LP	90%	13F overlay lists Bleichroeder LP as top holder; 44 tracked holders.

Curis, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CCCC	C4 Therapeutics, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
BPTH	Bio-Path Holdings, Inc.	100.00	1	['customer']
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2

Curis, Inc. Supply Chain